Company Overview of Implicit Bioscience Limited
Implicit Bioscience Limited operates as a clinical-stage immunotherapy drug development company. It develops drugs that modulate the host immune response to disease. The company develops small molecule dipeptide oglufanide disodium for community and hospital-acquired infections including those caused by bio-threat agents. It offers IC14, a clinical stage recombinant chimeric monoclonal antibody which recognizes and blocks the function of human CD14, a component of the innate inflammatory response to bacterial infection. Implicit Bioscience Limited was founded in 2004 and is based in Woolloongabba, Australia with additional operations in Coorparoo, Australia and Seattle, Washington.
32 Logan Rd
Woolloongabba, QLD 4102
Founded in 2004
61 7 3721 1242
Key Executives for Implicit Bioscience Limited
Similar Private Companies By Industry
|AbRegen Pty Ltd.||Asia|
|Advanced Wound Care Pty Ltd.||Asia|
|Agriliance Pty Ltd.||Asia|
|AION Diagnostics Limited||Asia|
|Aquaceutics Pty Ltd||Asia|
Recent Private Companies Transactions
September 5, 2016
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|The Advertising Council, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Implicit Bioscience Limited, please visit www.implicitbioscience.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.